We report interim (provisional) data from a first-in-human phase I/II open-label, dose-optimization study investigating the safety and efficacy of mRNA-3927 for PA ...
Moderna announced the preliminary results of a Phase I/II dose optimization and extension study to assess the efficacy and safety of mRNA-3927, an investigational mRNA treatment for propionic acidemia ...
Metabolic cardiomyopathy is an important diagnostic consideration in a young patient with unexplained ventricular dysfunction or sudden cardiac arrest. Propionic acidemia is an uncommon but important ...
Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events in patients with propionic acidemia. Moderna has announced promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback